Go Deep
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -19,037 | -5.6 | -1.65 | -0.48 | 666.64 |
| Oct 2026 | -19,194 | -5.9 | -1.74 | -0.48 | 702.61 |
| Oct 2026 | -19,233 | -5.6 | -1.76 | -0.48 | 712.21 |
| Oct 2026 | -19,006 | -5.2 | -1.63 | -0.48 | 655.43 |
| Oct 2026 | -19,041 | -5.6 | -1.65 | -0.48 | 664.66 |
| Oct 2026 | -19,158 | -5.8 | -1.72 | -0.48 | 693.11 |
| Oct 2026 | -19,049 | -5.6 | -1.65 | -0.48 | 664.91 |
| Oct 2026 | -19,041 | -5.6 | -1.65 | -0.48 | 661.68 |
| Oct 2026 | -18,544 | -4.6 | -1.35 | -0.48 | 544.05 |
Phathom Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 74,274,000.0 | 58,301,000.0 | 57,584,000.0 | 49,504,000.0 |
| Net Profit | -17,582,000.0 | -30,369,000.0 | -21,148,000.0 | -29,973,000.0 |
| EPS | -0.2 | -0.4 | -0.3 | -0.4 |
Phathom Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 175,110,000.0 | 55,252,000.0 | 682,000.0 | 0.0 | — |
| Net Profit | -221,247,000.0 | -334,326,000.0 | -201,592,000.0 | -197,723,000.0 | — |
| EPS | -3.0 | -5.3 | -3.9 | -5.0 | — |
Phathom Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 259,149,000.0 | 378,318,000.0 | 413,842,000.0 | 164,810,000.0 | — |
| Total Liabilities | 697,318,000.0 | 631,898,000.0 | 486,601,000.0 | 239,624,000.0 | — |
| Total Equity | -438,169,000.0 | -253,580,000.0 | -72,759,000.0 | -74,814,000.0 | — |
Owes vs Owns
Phathom Pharmaceuticals, Inc. owed $2.05 for every $1 it owned in Jun 2026, up from $1.45 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 2.05× | 2.69× | 1.67× | 1.18× | 1.45× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Phathom Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 50.2%Receivables 30.1%Inventory 2.1%Fixed assets (tangible) 1.4%Other assets 16.2%
How it's funded — Dec 2025
Long-term debt 30.0%Payables 0.7%Other liabilities 69.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 130.0 | 297.3 | 381.4 | 155.4 |
| Receivables | 78.1 | 38.8 | 1.6 | 0.0 |
| Inventory | 5.5 | 3.2 | 1.2 | 0.0 |
| Fixed assets (tangible) | 3.7 | 2.1 | 3.6 | 3.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 41.9 | 37.0 | 26.0 | 5.9 |
| Liabilities & equity | ||||
| Short-term debt | 0.6 | 0.5 | 0.7 | 0.7 |
| Long-term debt | 209.1 | 201.4 | 137.8 | 95.3 |
| Payables | 5.0 | 10.5 | 12.6 | 10.0 |
| Other liabilities | 482.6 | 419.5 | 335.4 | 133.7 |
| Shareholders' equity | -438.2 | -253.6 | -72.8 | -74.8 |
| Net tangible assets | -438.2 | -253.6 | -72.8 | -74.8 |
Phathom Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -166,775,000.0 | -266,770,000.0 | -137,580,000.0 | -146,530,000.0 | — |
| Investing Activities | -229,000.0 | -135,000.0 | -1,634,000.0 | -1,041,000.0 | — |
| Financing Activities | -288,000.0 | 182,774,000.0 | 367,580,000.0 | 120,042,000.0 | — |